Accomplishments in 2008 in the Management of Hepatobiliary Cancers

Por Zhu, Andrew X., El-Khoueiry, Anthony, Llovet, Josep M.
Publicado em 2009

Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

Por Kuang, Yuting, El-Khoueiry, Anthony, Taverna, Pietro, Ljungman, Mats, Neamati, Nouri
Publicado no Mol Oncol (2015)

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models

Por LaBonte, Melissa J., Wilson, Peter M., Fazzone, Will, Russell, Jared, Louie, Stan G., El-Khoueiry, Anthony, Lenz, Heinz-Josef, Ladner, Robert D.
Publicado em 2011

SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Por El-Khoueiry, Anthony B., Rankin, Cathryn J., Ben-Josef, Edgar, Lenz, Heinz-Josef, Gold, Philip J., Hamilton, R. Darryl, Govindarajan, Rangaswamy, Eng, Cathy, Blanke, Charles D.
Publicado em 2011

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group Study S0202

Por Iqbal, Syma, Rankin, Cathryn, Lenz, Heinz-Josef, Gold, Philip J., Ahmad, Syed A., El-Khoueiry, Anthony B., Messino, Michael J., Holcombe, Randall F., Blanke, Charles D.
Publicado em 2011

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with beva...

Por Pohl, Alexandra, El-Khoueiry, Anthony, Yang, Dongyun, Zhang, Wu, Lurje, Georg, Ning, Yan, Winder, Thomas, Hu-Lieskoven, Siwen, Iqbal, Sima, Danenberg, Kathleen D., Kahn, Michael, Teo, Jia-Ling, Shriki, Jabi, Stebbing, Justin, Lenz, Heinz-Josef
Publicado em 2012

Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Por Gerger, Armin, El-Khoueiry, Anthony, Zhang, Wu, Yang, Dongyun, Singh, Harpreet, Bohanes, Pierre, Ning, Yan, Winder, Thomas, LaBonte, Melissa J., Wilson, Peter M., Benhaim, Leonor, Paez, David, El-Khoueiry, Rita, Absenger, Gudrun, Lenz, Heinz-Josef
Publicado em 2011

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer (GC) patients after surgery with curative intent

Por Wakatsuki, Takeru, Stintzing, Sebastian, Zhang, Wu, Yang, Dongyun, Azuma, Mizutomo, Ning, Yan, Yamauchi, Shinichi, Matsusaka, Satoshi, Volz, Nico B., Sunakawa, Yu, Koizumi, Wasaburo, Watanabe, Masahiko, Barzi, Afsaneh, El Khoueiry, Anthony B, Shah, Manish A, Lenz, Heinz-Josef
Publicado em 2014

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine

Por Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.
Publicado no Cancer Chemother Pharmacol (2015)

Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma

Por Siegel, Abby B., El-Khoueiry, Anthony B., Finn, Richard S., Guthrie, Katherine A., Goyal, Abhishek, Venook, Alan P., Blanke, Charles D., Verna, Elizabeth C., Dove, Lorna, Emond, Jean, Kato, Tomoaki, Samstein, Benjamin, Busuttil, Ronald, Remotti, Helen, Coffey, Amy, Brown Jr, Robert S.
Publicado no Liver Cancer (2015)

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbla...

Por Ben-Josef, Edgar, Guthrie, Katherine A., El-Khoueiry, Anthony B., Corless, Christopher L., Zalupski, Mark M., Lowy, Andrew M., Thomas, Charles R., Alberts, Steven R., Dawson, Laura A., Micetich, Kenneth C., Thomas, Melanie B., Siegel, Abby B., Blanke, Charles D.
Publicado no J Clin Oncol (2015)

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Por Azad, Nilofer S., el-Khoueiry, Anthony, Yin, Jun, Oberg, Ann L., Flynn, Patrick, Adkins, Douglas, Sharma, Anup, Weisenberger, Daniel J., Brown, Thomas, Medvari, Prakriti, Jones, Peter A., Easwaran, Hariharan, Kamel, Ihab, Bahary, Nathan, Kim, George, Picus, Joel, Pitot, Henry C., Erlichman, Charles, Donehower, Ross, Shen, Hui, Laird, Peter W., Piekarz, Richard, Baylin, Stephen, Ahuja, Nita
Publicado no Oncotarget (2017)

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized...

Por Venook, Alan P., Niedzwiecki, Donna, Lenz, Heinz-Josef, Innocenti, Federico, Fruth, Briant, Meyerhardt, Jeffrey A., Schrag, Deborah, Greene, Claire, O’Neil, Bert H., Atkins, James Norman, Berry, Scott, Polite, Blase N., O’Reilly, Eileen M., Goldberg, Richard M., Hochster, Howard S., Schilsky, Richard L., Bertagnolli, Monica M., El-Khoueiry, Anthony B., Watson, Peter, Benson, Al B., Mulkerin, Daniel L., Mayer, Robert J., Blanke, Charles
Publicado no JAMA (2017)

AKT Inhibition in Solid Tumors With AKT1 Mutations

Por Hyman, David M., Smyth, Lillian M., Donoghue, Mark T.A., Westin, Shannon N., Bedard, Philippe L., Dean, Emma J., Bando, Hideaki, El-Khoueiry, Anthony B., Pérez-Fidalgo, José A., Mita, Alain, Schellens, Jan H.M., Chang, Matthew T., Reichel, Jonathan B., Bouvier, Nancy, Selcuklu, S. Duygu, Soumerai, Tara E., Torrisi, Jean, Erinjeri, Joseph P., Ambrose, Helen, Barrett, J. Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P.O., McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F., Chandarlapaty, Sarat, Solit, David B., Banerji, Udai, Baselga, José, Taylor, Barry S.
Publicado no J Clin Oncol (2017)